newsfilter
← Latest News
Business Wire·

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Investigator-initiated European study will evaluate a distinctive dual-biomarker precision-oncology strategy — PTGR1 overexpression combined with tumor-specific Nucleotide Excision Repair — in patients with advanced